Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

om placebo to I.V. golimumab during the trial (P < 0.001).  Patients randomized to I.V. golimumab and those in the crossover group had a mean change in total vdH-S score of 0.15 (+/- 1.83) and 0.12 (+/- 2.44), respectively, from week 24 to 52, supporting inhibition of structural damage progression in all patients receiving I.V. golimumab.

Significant proportions of patients receiving I.V. golimumab also demonstrated improvements in signs and symptoms compared with patients receiving placebo according to ACR scores, European League Against Rheumatism (EULAR)/Disease Activity Score (DAS) 28 C-reactive protein (CRP) response criteria and Health Assessment Questionnaire (HAQ) disability scores at weeks 14 and 24.  A majority of those patients who achieved ACR 20, ACR 50, ACR 70 and EULAR/DAS 28 CRP good/moderate response by week 24 maintained response through week 52 (82 percent of ACR20 responders; 71.7 percent of ACR 50 responders; 60.9 percent of ACR 70 responders; 80 percent demonstrating DAS28-CRP good/moderate response).  The EULAR/DAS 28 CRP is a measure of disease activity in patients with RA that is calculated by assessing the number of tender and swollen joints (among a total of 28), serum CRP level (indicator of inflammation), and the patient's assessment of global health. 

Through week 52 of the GO-FURTHER trial, the safety profile of I.V. golimumab remained consistent with previously reported week 24 data.  Through week 24, adverse events (AEs) occurred in 53 percent of patients receiving I.V. golimumab and 49 percent of patients receiving placebo, and serious AEs were reported in more I.V. golimumab-treated patients (4 percent) than placebo-treated patients (2 percent).  Rates of AEs and serious AEs at week 52 among patients receiving I.V. golimumab were 65 percent and 9 percent, respectively.  There were no serious opportunistic infections through week 52 of the study.  One case of tubercul
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 ... Market by Tumor (Breast, Lung, Prostate) Type (Protein & ... (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast ... is expected to reach around 17,689.0 Million USD by ... period of 2015 to 2020. Browse ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Ranibizumab ... Developed by Novartis, ranibizumab was approved by CFDA to ... Currently, only Lucentis, a product of Novartis, is available ... the first self- developed drug for the treatment of ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 51-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... DIEGO, Nov. 24 Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ... Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009 ... is being held at The New York Palace Hotel. ... will provide an overview of Anadys and its clinical development ...
... , POTOMAC, Md., Nov. 24 In ... has added Philadelphia jurors to her Thanksgiving gratitude list. ... I am so thankful to them," she said of Monday,s ... , Wisneski is among 12,000 women nationwide who have sued ...
Cached Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Maryland Woman Thankful for Wyeth Verdicts 2
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... Rio ... O’Shea to serve as the college’s Vice President of Strategic Initiatives and Information Services. ... eager to help the college expand its reach and impact through innovative technologies and ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... , ... Brands like Toppik , Eau Thermale Avene and Bliss are ... threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, ... for customers regardless of the item’s selling price.” , With competitive pricing in the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... center management, Decatur County Memorial Hospital recently transitioned management companies to partner with ... Center Management for their outpatient wound center. , Transitioning wound care management ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... of Experimental Medicine -, - Findings Underscore Versatility ... Antagonists as Possible ... TorreyPines Therapeutics, Inc.,(Nasdaq: TPTX ) today announced ... Hopkins University (JHU) for intellectual property,related to the novel ...
... Blue Cross and Blue Shield of,Florida ... been appointed Market,President - West Florida, effective ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000427/BLUELOGOA ), ... has served in a number of leadership ...
... May 1 Cadient Group, the,premier strategic interactive ... has appointed Barbara Dowling as Senior Vice,President, Customer ... on both the client and agency side, Barb ... to address business critical,issues. In this role, Dowling ...
... 1 Nu Skin Enterprises, Inc.,(NYSE: NUS ... a 9,percent improvement over the prior-year period. Earnings ... 31 percent increase compared to the same,quarter of ... 6 percent,by foreign currency fluctuations. Quarterly earnings per ...
... Calif., May 1 Cardiogenesis,Corporation (Pink Sheets: CGCP), ... first quarter ended March 31, 2008 prior to ... also said that President Richard P.,Lanigan and Senior ... will host an investor conference call that day ...
... Performs with Peerless Safety and Proven Efficacy in all Four ... Chambers of the Heart, Stereotaxis to Introduce ... ... May 1 Stereotaxis, Inc. (Nasdaq:,STXS), announced today that approximately 15,000 procedures have been,performed ...
Cached Medicine News:Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 2Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 3Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 4Health News:David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida 2Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 2Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 3Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 4Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 5Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 6Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 7Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 8Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 9Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 10Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 2Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 3Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 4
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) IgA isotype in human serum....
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgica...
Medicine Products: